RECRUITING

Pilot Trial of Homebound Stem Cell Transplantation

Talk to us

Conditions

Plasma Cell DyscrasiaHomeboundHomecare15-022

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

In this study, the investigators plan to see what happens when a person receives care in the home setting. They want to find out if caring for a patient who has been treated with an ASCT in the home setting is feasible. They want to find out what effects good and/or bad this will have on the patient's recovery and treatment after ASCT. Studies in other institutions have shown that providing care in the home setting after ASCT is safe, increases patient satisfaction, and can decrease the risk of infection. It is our hope that this new approach of providing care in the home setting will prove to be a feasible and safe option for patients at Memorial Sloan Kettering Cancer Center (MSK).

Official Title

Pilot Trial of Homebound Stem Cell Transplantation

Quick Facts

Study Start:2016-01
Study Completion:2025-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT02671448

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Diagnosis of Plasma cell dyscrasia
  2. * Treatment plan including Autologous HSCT
  3. * 18-80 years of age
  4. * Appropriate homebound setting as defined by one of the following:
  5. * Lodging at the MSK Residence.
  6. * Staying at home or a "home equivalent" in any one of the zip codes as outlined in the appendix. Home equivalent is defined as a residence which may or may not be the primary residence of the patient.
  7. * "Home equivalent" must pass the "Home Environment Screening Tool" for homebound stem cell transplantation (not required for other MSK recognized lodging facility).
  8. * Adequate caregiver support as defined by:
  9. * Single or multiple informal caregivers willing and able to provide 24 hour a day, seven day a week supervision of the transplant recipient in their home or "home-like" environment.
  10. * Caregiver willing and able to fulfill the basic stem cell transplant caregiver education requirements as determined by caregiver and healthcare team, including social worker
  11. * Have Wi-Fi connection
  12. * Appropriate third party payer coverage for "Homebound Stem Cell Transplant Program"
  13. * Both patient and caregiver willing to give and sign informed consent.
  1. * Patients with a documented active infection prior to starting their preparative regimen. This includes grade 3 or higher viral, bacterial, or fungal infection.
  2. * Uncontrolled arrhythmias
  3. * Active or uncontrolled pulmonary disease
  4. * Karnofsky Performance Scale (KPS) score \<80
  5. * Sorror Co-morbidity index ≥ 4 except in patients with history of resected cancers
  6. * Creatinine clearance (calculated or measured) of \< 50 cc/minute
  7. * Inability of patient or caregiver to speak or read English (we currently do not have the manpower to translate nor staff a multilingual homebound stem cell transplant program with adequate educational materials).
  8. * Inadequate housing arrangements
  9. * Inadequate caregiver arrangements

Contacts and Locations

Study Contact

Heather Landau, MD
CONTACT
ABMTTrials@mskcc.org
Sergio Giralt, MD
CONTACT
ABMTTrials@mskcc.org

Principal Investigator

Heather Landau, MD
PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center

Study Locations (Sites)

Memorial Sloan Kettering Cancer Center
New York, New York, 10065
United States

Collaborators and Investigators

Sponsor: Memorial Sloan Kettering Cancer Center

  • Heather Landau, MD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2016-01
Study Completion Date2025-01

Study Record Updates

Study Start Date2016-01
Study Completion Date2025-01

Terms related to this study

Keywords Provided by Researchers

  • Homebound
  • Homecare
  • 15-022

Additional Relevant MeSH Terms

  • Plasma Cell Dyscrasia